258 related articles for article (PubMed ID: 34309706)
1. Use and caregiver-reported efficacy of medical cannabis in children and adolescents in Switzerland.
Zürcher K; Dupont C; Weber P; Grunt S; Wilhelm I; Eigenmann DE; Reichmuth ML; Fankhauser M; Egger M; Fenner L
Eur J Pediatr; 2022 Jan; 181(1):335-347. PubMed ID: 34309706
[TBL] [Abstract][Full Text] [Related]
2. Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: A survey of the status in the chapters of the European Pain Federation.
Krcevski-Skvarc N; Wells C; Häuser W
Eur J Pain; 2018 Mar; 22(3):440-454. PubMed ID: 29134767
[TBL] [Abstract][Full Text] [Related]
3. Tetrahydrocannabinol and Cannabidiol Use in an Outpatient Palliative Medicine Population.
Highet BH; Lesser ER; Johnson PW; Kaur JS
Am J Hosp Palliat Care; 2020 Aug; 37(8):589-593. PubMed ID: 31986898
[TBL] [Abstract][Full Text] [Related]
4. Cannabis, cannabidiol, and epilepsy--from receptors to clinical response.
Szaflarski JP; Bebin EM
Epilepsy Behav; 2014 Dec; 41():277-82. PubMed ID: 25282526
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals.
Legare CA; Raup-Konsavage WM; Vrana KE
Pharmacology; 2022; 107(3-4):131-149. PubMed ID: 35093949
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Use of Δ9-THC and Cannabidiol: Evaluation of a New Extraction Procedure for the Preparation of Cannabis-based Olive Oil.
Morini L; Porro G; Liso M; Groppi A
Curr Pharm Biotechnol; 2017; 18(10):828-833. PubMed ID: 29189144
[TBL] [Abstract][Full Text] [Related]
7. Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort.
Baron EP; Lucas P; Eades J; Hogue O
J Headache Pain; 2018 May; 19(1):37. PubMed ID: 29797104
[TBL] [Abstract][Full Text] [Related]
8. Δ9-Tetrahydrocannabinol and Cannabidiol Time Courses in the Sera of "Light Cannabis" Smokers: Discriminating Light Cannabis Use from Illegal and Medical Cannabis Use.
Pichini S; Mannocchi G; Berretta P; Zaami S; Pirani F; Pacifici R; Busardò FP
Ther Drug Monit; 2020 Feb; 42(1):151-156. PubMed ID: 31389860
[TBL] [Abstract][Full Text] [Related]
9. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG
JAMA; 2020 Dec; 324(21):2177-2186. PubMed ID: 33258890
[TBL] [Abstract][Full Text] [Related]
10. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
11. Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review.
Sarris J; Sinclair J; Karamacoska D; Davidson M; Firth J
BMC Psychiatry; 2020 Jan; 20(1):24. PubMed ID: 31948424
[TBL] [Abstract][Full Text] [Related]
12. Authorization Patterns, Safety, and Effectiveness of Medical Cannabis in Quebec.
Kalaba M; MacNair L; Peters EN; Eglit GML; Rapin L; Hage CE; Prosk E; Ware MA
Cannabis Cannabinoid Res; 2021 Dec; 6(6):564-572. PubMed ID: 33998902
[No Abstract] [Full Text] [Related]
13. Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents - An observational, longitudinal study.
Hausman-Kedem M; Menascu S; Kramer U
Brain Dev; 2018 Aug; 40(7):544-551. PubMed ID: 29674131
[TBL] [Abstract][Full Text] [Related]
14. Safety and pharmacokinetics of medical cannabis preparation in a monocentric series of young patients with drug resistant epilepsy.
Gherzi M; Milano G; Fucile C; Calevo MG; Mancardi MM; Nobili L; Astuni P; Marini V; Barco S; Cangemi G; Manfredini L; Mattioli F; De Grandis E
Complement Ther Med; 2020 Jun; 51():102402. PubMed ID: 32507423
[TBL] [Abstract][Full Text] [Related]
15. Medicinal cannabis for the treatment of anxiety disorders.
Berger M; Amminger GP; McGregor IS
Aust J Gen Pract; 2022 Aug; 51(8):586-592. PubMed ID: 35908759
[TBL] [Abstract][Full Text] [Related]
16. Cannabidiol (CBD) and other drug use among young adults who use cannabis in Los Angeles.
Fedorova EV; Wong CF; Ataiants J; Iverson E; Conn BM; Lankenau SE
Drug Alcohol Depend; 2021 Apr; 221():108648. PubMed ID: 33676073
[TBL] [Abstract][Full Text] [Related]
17. Cannabis constituents reduce seizure behavior in chemically-induced and scn1a-mutant zebrafish.
Thornton C; Dickson KE; Carty DR; Ashpole NM; Willett KL
Epilepsy Behav; 2020 Sep; 110():107152. PubMed ID: 32585475
[TBL] [Abstract][Full Text] [Related]
18. Medical Cannabis Received by Patients According to Qualifying Condition in a US State Cannabis Program: Product Choice, Dosing, and Age-Related Trends.
Lyu X; Illamola SM; Marino SE; Leppik IE; Dahmer S; Lehfeldt P; Conway JM; Remmel RP; Kingsley K; Birnbaum AK
Curr Ther Res Clin Exp; 2023; 99():100709. PubMed ID: 37538850
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology of Medical Cannabis.
Amin MR; Ali DW
Adv Exp Med Biol; 2019; 1162():151-165. PubMed ID: 31332738
[TBL] [Abstract][Full Text] [Related]
20. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
